Sanofi Terminates Nurix’s Oral STAT6 Degrader Programme

On November 3, 2026, Nurix Therapeutics announced that Sanofi had notified the company of its decision to discontinue the Phase 1 clinical trial of SAR448272 and terminate its development programme.

Also identified as NX-3911, SAR448272 is an oral targeted protein degrader engineered to induce the degradation of signal transducer and activator of transcription 6 (STAT6), a key transcription factor involved in immune signalling. STAT6 is a central component of the interleukin-4 (IL-4) and interleukin-13 (IL-13) signalling pathways, which drive type 2 inflammation and contribute to conditions such as atopic dermatitis and asthma. The candidate was discovered and developed under the Nurix–Sanofi collaboration to explore targeted protein degradation (TPD) for inflammatory diseases.

Neither Sanofi nor Nurix disclosed the rationale behind the discontinuation, nor did they share clinical efficacy, pharmacological, or safety data from the study. Consequently, available information does not indicate whether the decision was driven by clinical findings, portfolio reprioritization, or strategic considerations.

Financial & Collaboration Implications

The discontinuation removes a significant source of potential future milestone and royalty revenue for Nurix:

• Received Payments: In August 2026, Nurix received a $10 million milestone payment following Sanofi’s initiation of the Phase 1 trial. This payment remains recognized and unaffected by the decision.
• Foregone Future Milestones: Nurix is no longer eligible for the approximately $453 million in remaining development, regulatory, and commercial milestone payments associated with the STAT6 programme, as well as potential downstream royalties.
• Broader Sanofi Partnership Intact: The termination is program-specific and does not end the overarching 2019 Nurix–Sanofi collaboration.
  • Under the original agreement, Nurix deployed its proprietary DEL-AI drug discovery platform to identify agents utilizing E3 ligases for protein degradation.
  • In 2025, Sanofi exercised licence extension options for two programmes targeting transcription factors in autoimmune and inflammatory diseases (including STAT6 and another undisclosed target).
  • Nurix retains co-development and co-promotion options in the United States for qualifying collaboration programmes upon achieving clinical proof of concept, and remains eligible for milestones and royalties from other licensed programmes Sanofi chooses to advance.

Balance Sheet & Clinical Pipeline Resilience

Nurix confirmed that the discontinuation does not alter its cash runway guidance. As of August 31, 2026, the company reported $1.1 billion in cash, cash equivalents, and marketable securities, which it expects will fund operations into the second half of 2029.

Nurix’s remaining clinical-stage portfolio spans key oncology and autoimmune programs:

• Bexobrutideg (BTK Degrader): Partnered with Roche; currently advancing in a Phase 3 trial for patients with chronic lymphocytic leukaemia (CLL).
• NX-1607 (CBL-B Inhibitor): Wholly owned candidate progressing through multiple Phase 1b cohorts targeting lung, colon, prostate, and melanoma cancers.
• GS-6791 / NX-0479 (IRAK4 Degrader): Partnered with Gilead; advancing through Phase 1 trials for rheumatoid arthritis.
• Preclinical Assets: Continued advancement of early-stage targeted protein degraders and degrader antibody conjugates (DACs).

Clinical & Strategic Interpretation

The decision removes an oral STAT6 degrader early in its first-in-human evaluation. While the termination eliminates ~$453 million in prospective milestone value, the lack of disclosed safety or efficacy data means the decision should not be interpreted as a validation failure of STAT6 as a therapeutic target, but rather a failure/reprioritization of this specific chemical entity (SAR448272).

For Nurix investors and partners, the financial loss is strictly limited to the unrealized potential milestones of SAR448272, while the company maintains a robust balance sheet ($1.1B) and multiple advanced clinical assets across oncology and immunology.

Reference

Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272, Nurix, 03 November 2026